CL2008001135A1 - Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida en forma de hidrato, solvato, base o sal de adicion a un acido para preparar un medicamento util en el tratamiento de traumatismos cerebrales. - Google Patents

Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida en forma de hidrato, solvato, base o sal de adicion a un acido para preparar un medicamento util en el tratamiento de traumatismos cerebrales.

Info

Publication number
CL2008001135A1
CL2008001135A1 CL2008001135A CL2008001135A CL2008001135A1 CL 2008001135 A1 CL2008001135 A1 CL 2008001135A1 CL 2008001135 A CL2008001135 A CL 2008001135A CL 2008001135 A CL2008001135 A CL 2008001135A CL 2008001135 A1 CL2008001135 A1 CL 2008001135A1
Authority
CL
Chile
Prior art keywords
oxido
cyclopropylmethoxy
carboxamide
pyridin
dichloro
Prior art date
Application number
CL2008001135A
Other languages
English (en)
Inventor
Goyet Philippe Perron Corinne Delay
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001135(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2008001135A1 publication Critical patent/CL2008001135A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos cerebrales.
CL2008001135A 2007-04-19 2008-04-18 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida en forma de hidrato, solvato, base o sal de adicion a un acido para preparar un medicamento util en el tratamiento de traumatismos cerebrales. CL2008001135A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702852A FR2915099B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens

Publications (1)

Publication Number Publication Date
CL2008001135A1 true CL2008001135A1 (es) 2009-01-16

Family

ID=38819821

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001135A CL2008001135A1 (es) 2007-04-19 2008-04-18 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida en forma de hidrato, solvato, base o sal de adicion a un acido para preparar un medicamento util en el tratamiento de traumatismos cerebrales.

Country Status (34)

Country Link
US (1) US9393236B2 (es)
EP (1) EP2146713B1 (es)
JP (1) JP5386476B2 (es)
KR (1) KR101460828B1 (es)
CN (1) CN101663036B (es)
AR (1) AR066105A1 (es)
AT (1) ATE532513T1 (es)
AU (1) AU2008257319B2 (es)
BR (1) BRPI0810423A2 (es)
CA (1) CA2684171C (es)
CL (1) CL2008001135A1 (es)
CO (1) CO6140028A2 (es)
CY (1) CY1112282T1 (es)
DK (1) DK2146713T3 (es)
EA (1) EA015503B1 (es)
ES (1) ES2376023T3 (es)
FR (1) FR2915099B1 (es)
HK (1) HK1141724A1 (es)
HR (1) HRP20120130T1 (es)
IL (1) IL201447A (es)
JO (1) JO2861B1 (es)
MA (1) MA31368B1 (es)
ME (2) ME00938B (es)
MX (1) MX2009011214A (es)
MY (1) MY147207A (es)
NZ (1) NZ580484A (es)
PA (1) PA8776701A1 (es)
PL (1) PL2146713T3 (es)
PT (1) PT2146713E (es)
RS (1) RS52130B (es)
SI (1) SI2146713T1 (es)
TW (1) TWI423800B (es)
UY (1) UY31034A1 (es)
WO (1) WO2008145838A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500094A (ja) * 2012-11-28 2016-01-07 サノフイ ４−（シクロプロピルメトキシ）−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−メトキシピリジン−２−カルボキサミドの結晶形態の製造方法およびその結晶形態

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1273326A (en) * 1917-08-22 1918-07-23 George H Bugenhagen Transmission mechanism.
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
EP0711282B1 (en) * 1993-07-28 2002-06-05 Aventis Pharma Limited Compounds as pde iv and tnf inhibitors
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9507297D0 (en) * 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
TR200103531T2 (tr) * 1999-06-07 2002-06-21 Warner Lambert Company Trisklik analjezikler
EP1244649B1 (en) 1999-12-23 2005-03-02 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
CA2439691A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
AU2003281219A1 (en) 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
GB2406856B (en) 2003-10-07 2005-10-19 Renovis Inc Amide compounds as ion channel ligands and uses thereof
EP1888528A2 (en) * 2005-06-10 2008-02-20 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20070021451A1 (en) 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury
FR2915098B1 (fr) 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Also Published As

Publication number Publication date
MX2009011214A (es) 2009-11-02
EA200970968A1 (ru) 2010-02-26
KR20090130058A (ko) 2009-12-17
FR2915099A1 (fr) 2008-10-24
ES2376023T3 (es) 2012-03-08
KR101460828B1 (ko) 2014-11-11
CN101663036A (zh) 2010-03-03
MA31368B1 (fr) 2010-05-03
MY147207A (en) 2012-11-14
JO2861B1 (en) 2015-03-15
US20100130553A1 (en) 2010-05-27
TWI423800B (zh) 2014-01-21
RS52130B (en) 2012-08-31
SI2146713T1 (sl) 2012-03-30
JP5386476B2 (ja) 2014-01-15
AU2008257319B2 (en) 2013-07-25
IL201447A (en) 2013-07-31
EP2146713B1 (fr) 2011-11-09
UY31034A1 (es) 2008-11-28
IL201447A0 (en) 2010-05-31
ME01273B (me) 2013-06-20
CN101663036B (zh) 2012-06-20
NZ580484A (en) 2011-06-30
HRP20120130T1 (hr) 2012-03-31
ATE532513T1 (de) 2011-11-15
BRPI0810423A2 (pt) 2014-10-14
AU2008257319A1 (en) 2008-12-04
WO2008145838A2 (fr) 2008-12-04
AR066105A1 (es) 2009-07-22
TW200914009A (en) 2009-04-01
JP2010524903A (ja) 2010-07-22
HK1141724A1 (es) 2010-11-19
EP2146713A2 (fr) 2010-01-27
DK2146713T3 (da) 2012-03-05
EA015503B1 (ru) 2011-08-30
ME00938B (me) 2012-06-20
PL2146713T3 (pl) 2012-04-30
CY1112282T1 (el) 2015-12-09
US9393236B2 (en) 2016-07-19
CA2684171C (fr) 2015-12-01
FR2915099B1 (fr) 2009-06-05
CO6140028A2 (es) 2010-03-19
PT2146713E (pt) 2012-02-07
WO2008145838A3 (fr) 2009-03-26
CA2684171A1 (fr) 2008-12-04
PA8776701A1 (es) 2008-11-19

Similar Documents

Publication Publication Date Title
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
TN2012000609A1 (en) Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
MX2015014298A (es) Compuestos de dihidropirido pirimidina como inhibidores de autotaxina.
UA115320C2 (uk) Інгібітори кінази
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
TN2012000608A1 (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
ECSP088820A (es) Síntesis de acil-amino-alquenilen-amidas utiles como antagonistas de la sustancia p.
EA201100969A1 (ru) Солевые формы органического соединения
CL2013003044A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades.
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
CL2008001658A1 (es) Composicion farmaceutica que comprende mesilato de imatinib amorfo y un principio de formulacion que estabiliza la forma amorfa; y su uso para tratar leucemia mieloide cronica avanzada y recientemente diagnosticada, leucemia mielomonocitica cronica, glioblastoma multiforme, entre otras.
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
CL2014002847A1 (es) Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras.
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
EA201101207A1 (ru) Применение антагонистов рецептора nk
MX2013010308A (es) 2,4-pirimidindiaminas sustituidas para uso en lupus discoide.
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
HRP20110459T1 (hr) Upotreba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju ozljeda kralježnične moždine
CL2016002721A1 (es) Un profármaco de 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-prolina
CL2008001135A1 (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida en forma de hidrato, solvato, base o sal de adicion a un acido para preparar un medicamento util en el tratamiento de traumatismos cerebrales.
CL2015003535A1 (es) Composiciones farmacéuticas.
RS51869B (en) USE OF 4-CYCLOPROPYLMETOXY-N- (3,5-DICHLORO-1-OXIDO-PYRIDIN-4-IL) -5- (METHOXY) PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE